Ginsenosides: changing the basic hallmarks of cancer cells to achieve the purpose of treating breast cancer

In 2021, breast cancer accounted for a substantial proportion of cancer cases and represented the second leading cause of cancer deaths among women worldwide. Although tumor cells originate from normal cells in the human body, they possess distinct biological characteristics resulting from changes i...

Full description

Saved in:
Bibliographic Details
Published inChinese medicine Vol. 18; no. 1; pp. 1 - 28
Main Authors Jiang, Rui-yuan, Fang, Zi-ru, Zhang, Huan-ping, Xu, Jun-yao, Zhu, Jia-yu, Chen, Ke-yu, Wang, Wei, Jiang, Xiao, Wang, Xiao-jia
Format Journal Article
LanguageEnglish
Published London BioMed Central 25.09.2023
BioMed Central Ltd
BMC
Subjects
Acupuncture
Angiogenesis
Apoptosis
Bone density
Breast cancer
Cancer
Cancer cells
Cancer therapies
Care and treatment
Cell death
Cell growth
Chemotherapy
Clinical medicine
Complementary & Alternative Medicine
Development and progression
Drugs
Epithelial-mesenchymal transition
Genetic aspects
Ginsenoside
Ginsenosides
Hallmarks of cancer
Health aspects
Herbal medicine
Inflammation
Medical research
Medicine
Medicine & Public Health
Metastasis
Oncology, Experimental
Pathogenesis
Patients
Physiological aspects
Quality of life
Review
Structure-function relationships
Toxicity
Traditional Chinese Medicine
Tumor cells
Tumors
United States > US
Epithelial-mesenchymal transition
Hallmarks of cancer
Cell growth
Breast cancer
Ginsenoside
Apoptosis
Online AccessGet full text
ISSN1749-8546
1749-8546
DOI10.1186/s13020-023-00822-9

Cover

Abstract In 2021, breast cancer accounted for a substantial proportion of cancer cases and represented the second leading cause of cancer deaths among women worldwide. Although tumor cells originate from normal cells in the human body, they possess distinct biological characteristics resulting from changes in gene structure and function of cancer cells in contrast with normal cells. These distinguishing features, known as hallmarks of cancer cells, differ from those of normal cells. The hallmarks primarily include high metabolic activity, mitochondrial dysfunction, and resistance to cell death. Current evidence suggests that the fundamental hallmarks of tumor cells affect the tissue structure, function, and metabolism of tumor cells and their internal and external environment. Therefore, these fundamental hallmarks of tumor cells enable tumor cells to proliferate, invade and avoid apoptosis. Modifying these hallmarks of tumor cells represents a new and potentially promising approach to tumor treatment. The key to breast cancer treatment lies in identifying the optimal therapeutic agent with minimal toxicity to normal cells, considering the specific types of tumor cells in patients. Some herbal medicines contain active ingredients which can precisely achieve this purpose. In this review, we introduce Ginsenoside's mechanism and research significance in achieving the therapeutic effect of breast cancer by changing the functional hallmarks of tumor cells, providing a new perspective for the potential application of Ginsenoside as a therapeutic drug for breast cancer.
AbstractList In 2021, breast cancer accounted for a substantial proportion of cancer cases and represented the second leading cause of cancer deaths among women worldwide. Although tumor cells originate from normal cells in the human body, they possess distinct biological characteristics resulting from changes in gene structure and function of cancer cells in contrast with normal cells. These distinguishing features, known as hallmarks of cancer cells, differ from those of normal cells. The hallmarks primarily include high metabolic activity, mitochondrial dysfunction, and resistance to cell death. Current evidence suggests that the fundamental hallmarks of tumor cells affect the tissue structure, function, and metabolism of tumor cells and their internal and external environment. Therefore, these fundamental hallmarks of tumor cells enable tumor cells to proliferate, invade and avoid apoptosis. Modifying these hallmarks of tumor cells represents a new and potentially promising approach to tumor treatment. The key to breast cancer treatment lies in identifying the optimal therapeutic agent with minimal toxicity to normal cells, considering the specific types of tumor cells in patients. Some herbal medicines contain active ingredients which can precisely achieve this purpose. In this review, we introduce Ginsenoside's mechanism and research significance in achieving the therapeutic effect of breast cancer by changing the functional hallmarks of tumor cells, providing a new perspective for the potential application of Ginsenoside as a therapeutic drug for breast cancer.
In 2021, breast cancer accounted for a substantial proportion of cancer cases and represented the second leading cause of cancer deaths among women worldwide. Although tumor cells originate from normal cells in the human body, they possess distinct biological characteristics resulting from changes in gene structure and function of cancer cells in contrast with normal cells. These distinguishing features, known as hallmarks of cancer cells, differ from those of normal cells. The hallmarks primarily include high metabolic activity, mitochondrial dysfunction, and resistance to cell death. Current evidence suggests that the fundamental hallmarks of tumor cells affect the tissue structure, function, and metabolism of tumor cells and their internal and external environment. Therefore, these fundamental hallmarks of tumor cells enable tumor cells to proliferate, invade and avoid apoptosis. Modifying these hallmarks of tumor cells represents a new and potentially promising approach to tumor treatment. The key to breast cancer treatment lies in identifying the optimal therapeutic agent with minimal toxicity to normal cells, considering the specific types of tumor cells in patients. Some herbal medicines contain active ingredients which can precisely achieve this purpose. In this review, we introduce Ginsenoside's mechanism and research significance in achieving the therapeutic effect of breast cancer by changing the functional hallmarks of tumor cells, providing a new perspective for the potential application of Ginsenoside as a therapeutic drug for breast cancer. Keywords: Ginsenoside, Breast cancer, Hallmarks of cancer, Apoptosis, Epithelial-mesenchymal transition, Cell growth
Abstract In 2021, breast cancer accounted for a substantial proportion of cancer cases and represented the second leading cause of cancer deaths among women worldwide. Although tumor cells originate from normal cells in the human body, they possess distinct biological characteristics resulting from changes in gene structure and function of cancer cells in contrast with normal cells. These distinguishing features, known as hallmarks of cancer cells, differ from those of normal cells. The hallmarks primarily include high metabolic activity, mitochondrial dysfunction, and resistance to cell death. Current evidence suggests that the fundamental hallmarks of tumor cells affect the tissue structure, function, and metabolism of tumor cells and their internal and external environment. Therefore, these fundamental hallmarks of tumor cells enable tumor cells to proliferate, invade and avoid apoptosis. Modifying these hallmarks of tumor cells represents a new and potentially promising approach to tumor treatment. The key to breast cancer treatment lies in identifying the optimal therapeutic agent with minimal toxicity to normal cells, considering the specific types of tumor cells in patients. Some herbal medicines contain active ingredients which can precisely achieve this purpose. In this review, we introduce Ginsenoside's mechanism and research significance in achieving the therapeutic effect of breast cancer by changing the functional hallmarks of tumor cells, providing a new perspective for the potential application of Ginsenoside as a therapeutic drug for breast cancer.
In 2021, breast cancer accounted for a substantial proportion of cancer cases and represented the second leading cause of cancer deaths among women worldwide. Although tumor cells originate from normal cells in the human body, they possess distinct biological characteristics resulting from changes in gene structure and function of cancer cells in contrast with normal cells. These distinguishing features, known as hallmarks of cancer cells, differ from those of normal cells. The hallmarks primarily include high metabolic activity, mitochondrial dysfunction, and resistance to cell death. Current evidence suggests that the fundamental hallmarks of tumor cells affect the tissue structure, function, and metabolism of tumor cells and their internal and external environment. Therefore, these fundamental hallmarks of tumor cells enable tumor cells to proliferate, invade and avoid apoptosis. Modifying these hallmarks of tumor cells represents a new and potentially promising approach to tumor treatment. The key to breast cancer treatment lies in identifying the optimal therapeutic agent with minimal toxicity to normal cells, considering the specific types of tumor cells in patients. Some herbal medicines contain active ingredients which can precisely achieve this purpose. In this review, we introduce Ginsenoside's mechanism and research significance in achieving the therapeutic effect of breast cancer by changing the functional hallmarks of tumor cells, providing a new perspective for the potential application of Ginsenoside as a therapeutic drug for breast cancer.In 2021, breast cancer accounted for a substantial proportion of cancer cases and represented the second leading cause of cancer deaths among women worldwide. Although tumor cells originate from normal cells in the human body, they possess distinct biological characteristics resulting from changes in gene structure and function of cancer cells in contrast with normal cells. These distinguishing features, known as hallmarks of cancer cells, differ from those of normal cells. The hallmarks primarily include high metabolic activity, mitochondrial dysfunction, and resistance to cell death. Current evidence suggests that the fundamental hallmarks of tumor cells affect the tissue structure, function, and metabolism of tumor cells and their internal and external environment. Therefore, these fundamental hallmarks of tumor cells enable tumor cells to proliferate, invade and avoid apoptosis. Modifying these hallmarks of tumor cells represents a new and potentially promising approach to tumor treatment. The key to breast cancer treatment lies in identifying the optimal therapeutic agent with minimal toxicity to normal cells, considering the specific types of tumor cells in patients. Some herbal medicines contain active ingredients which can precisely achieve this purpose. In this review, we introduce Ginsenoside's mechanism and research significance in achieving the therapeutic effect of breast cancer by changing the functional hallmarks of tumor cells, providing a new perspective for the potential application of Ginsenoside as a therapeutic drug for breast cancer.
ArticleNumber 125
Audience Academic
Author Jiang, Xiao
Wang, Xiao-jia
Xu, Jun-yao
Chen, Ke-yu
Wang, Wei
Zhang, Huan-ping
Jiang, Rui-yuan
Fang, Zi-ru
Zhu, Jia-yu
Author_xml – sequence: 1
  givenname: Rui-yuan
  surname: Jiang
  fullname: Jiang, Rui-yuan
  organization: Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang Chinese Medical University
– sequence: 2
  givenname: Zi-ru
  surname: Fang
  fullname: Fang, Zi-ru
  organization: Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang Chinese Medical University
– sequence: 3
  givenname: Huan-ping
  surname: Zhang
  fullname: Zhang, Huan-ping
  organization: Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Wenzhou Medical University
– sequence: 4
  givenname: Jun-yao
  surname: Xu
  fullname: Xu, Jun-yao
  organization: Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences
– sequence: 5
  givenname: Jia-yu
  surname: Zhu
  fullname: Zhu, Jia-yu
  organization: Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang Chinese Medical University
– sequence: 6
  givenname: Ke-yu
  surname: Chen
  fullname: Chen, Ke-yu
  organization: Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang Chinese Medical University
– sequence: 7
  givenname: Wei
  surname: Wang
  fullname: Wang, Wei
  organization: Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Wenzhou Medical University
– sequence: 8
  givenname: Xiao
  surname: Jiang
  fullname: Jiang, Xiao
  email: jiangx1985@gxtcmu.edu.cn
  organization: Department of Basic Medical Sciences, Guangxi University of Chinese Medicine
– sequence: 9
  givenname: Xiao-jia
  orcidid: 0000-0002-7005-0842
  surname: Wang
  fullname: Wang, Xiao-jia
  email: wxiaojia0803@163.com
  organization: Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences
BookMark eNp9ks1u3CAUha0qVfPTvkBXlipV3Ti9gI2hmyqK2jRSpG7aNcL4ekzigSngSHn74plRk4mqiIURnPOBD-e0OHLeYVG8J3BOiOCfI2FAoQLKKgBBaSVfFSekrWUlmpofPZkfF6cx3gI0rGHiTXHM2rzTcDgp7q6si-h8tD3GL6UZtVtZtyrTiGWnozXlqKdprcNdLP1QGu0MhtLgNMUy-VKb0eI9buWbOWx8xEWWAuq0YLo8iWlve1u8HvQU8d3-e1b8_v7t1-WP6ubn1fXlxU1lOOGp6gHrFrTktDc9Y5rVoBkwYkgDAwc-MEJaaBk12BPe8p4PIEzN0TSS1i2ys-J6x-29vlWbYPP1H5TXVm0XfFgpHZI1E6pO5iRFRwQOXS0lk8Abw8xQa8l0PTSZ9XXH2szdGnuDLgU9HUAPd5wd1crfKwINEZK1mfBpTwj-z4wxqbWNS4DaoZ-jooJLSkEQyNIPz6S3fg4uZ5VVy5O1XLSPqpXOf2Dd4PPBZoGqi5ZzzhiFhXX-H1UePa6tyUUabF4_MHx8YhhRT2mMfpqT9S4eCulOaIKPMeDwLw0Caimm2hVT5WKqbTGVzCbxzGRs0gs7X8tOL1vZzhrzOW6F4TGVF1x_AfYn9Uo
CitedBy_id crossref_primary_10_3390_nutraceuticals4040027
crossref_primary_10_3390_technologies13010007
crossref_primary_10_3389_fphar_2024_1408993
crossref_primary_10_1080_03639045_2025_2483425
crossref_primary_10_3390_ph17050598
Cites_doi 10.1002/rcm.1862
10.1038/nature15260
10.1016/j.cmet.2022.01.007
10.1016/j.jgr.2017.04.011
10.1007/s12272-021-01345-3
10.1016/j.pharmthera.2017.08.009
10.1200/JCO.2014.59.4358
10.1016/j.gendis.2018.05.001
10.1038/nature14583
10.1089/acm.2011.0591
10.26651/allelo.j/2021-54-1-1350
10.3389/fcvm.2020.00026
10.1111/cpr.13246
10.3390/ijms23179521
10.1016/j.phrs.2019.02.003
10.3346/jkms.2001.16.S.S6
10.3389/fphar.2021.801662
10.1101/cshperspect.a006080
10.1080/19768354.2018.1545696
10.3390/nu12010246
10.1016/j.it.2022.04.010
10.1007/s11101-019-09628-w
10.1016/j.cell.2017.01.002
10.1016/j.jgr.2021.05.004
10.1248/cpb.57.1412
10.1038/nri3191
10.1039/D2GC02639B
10.1002/(SICI)1097-0215(19970529)71:5<787::AID-IJC16>3.0.CO;2-5
10.1016/j.jchromb.2010.06.019
10.1158/2159-8290.CD-15-0563
10.1126/science.1228522
10.7717/peerj.9281
10.1002/jbt.22945
10.5142/jgr.2013.37.124
10.1016/j.patbio.2012.05.012
10.1007/s10549-012-2289-9
10.3390/ijms221910458
10.1093/carcin/bgv123
10.1016/j.tranon.2020.100773
10.1039/C8RA04879G
10.1136/heartjnl-2017-312103
10.3389/fcell.2022.1068720
10.1189/jlb.1107774
10.1155/2020/8886955
10.1142/S0192415X22500720
10.3389/fcimb.2022.853981
10.3390/ph15050626
10.1038/s41556-018-0201-5
10.2144/fsoa-2020-0076
10.1016/j.bbrc.2021.10.067
10.1126/sciadv.abj1262
10.1186/s12951-022-01623-2
10.1093/annonc/mdz173
10.1080/13813450801900645
10.1016/j.cell.2011.02.013
10.1016/j.jgr.2021.11.004
10.3892/mmr.2012.981
10.1016/j.jare.2022.09.007
10.1001/jamanetworkopen.2022.54677
10.1088/1361-6528/abe1f0
10.1016/j.intimp.2020.106535
10.1007/s11655-007-9002-6
10.1016/j.jep.2008.12.012
10.1002/bies.201000016
10.3390/cancers15041335
10.3390/pr9081344
10.2147/IJN.S221328
10.3322/caac.21708
10.1016/j.tox.2019.02.010
10.1002/ptr.6636
10.1016/j.cca.2019.01.011
10.1007/s12272-019-01115-2
10.1042/BST20110609
10.1007/s12094-019-02187-8
10.1148/radiol.2016150719
10.1038/srep33709
10.1016/j.bbrc.2018.03.174
10.3390/medicines6010017
10.1586/14737159.2015.1084229
10.1016/j.coi.2014.01.004
10.1016/j.jchromb.2004.11.036
10.1371/journal.pone.0240533
10.3322/caac.21397
10.1016/j.tibs.2015.12.001
10.2174/1568026619666191018100848
10.2174/1874467214666210120153348
10.1016/j.tem.2004.05.011
10.1002/cpdd.877
10.3390/ijms23169077
10.1038/s41571-021-00588-9
10.3390/jcm9010084
10.1155/2016/5738694
10.1172/JCI45014
10.1038/nrc.2015.2
10.3109/13880209.2015.1101142
10.1038/s41571-020-0341-y
10.1142/S0192415X18500702
10.3390/biom11010118
10.1016/j.bbcan.2017.06.006
10.1039/C8FO01122B
10.1158/2159-8290.CD-21-1059
10.1016/j.jep.2014.04.051
10.1007/s11684-020-0793-6
10.1001/jamaoncol.2018.7147
10.1038/nrclinonc.2016.144
10.1038/s42255-020-00317-z
10.1016/j.semcancer.2019.12.018
10.1016/j.biopha.2020.109891
10.3390/ph14070633
10.3892/ijmm.2013.1519
10.1016/j.jgr.2019.02.004
10.18632/aging.203131
10.18632/oncotarget.12059
10.1007/s12195-017-0485-8
10.3390/ijms23042288
10.1016/j.cell.2009.08.007
10.3390/cancers14030474
10.3389/fimmu.2020.00940
10.1016/j.jgr.2017.05.003
10.1016/j.bcp.2022.115101
10.1007/s12272-022-01377-3
10.1002/rcm.9083
10.1016/j.biopha.2017.02.038
10.1038/nrc3603
10.1097/CM9.0000000000000498
10.1016/j.jff.2019.04.019
10.1016/j.tig.2021.06.014
10.1039/C5AY01365H
10.18632/oncotarget.9059
10.1016/j.prp.2022.153956
10.1128/MCB.20.21.8069-8083.2000
10.3390/biom10040528
10.3390/ijms19113466
10.1016/j.jgr.2018.03.004
10.1186/1749-8546-5-19
10.1016/j.fct.2011.06.020
10.1016/j.semcancer.2015.02.006
10.3724/abbs.2022039
10.3892/or.2017.5652
10.1016/j.jgr.2018.05.004
10.1002/cam4.2474
10.1371/journal.pone.0002697
10.5142/jgr.2012.36.1.102
10.1142/S0192415X19500848
10.1093/carcin/bgt480
10.1039/C5TB02305J
10.3389/fphar.2021.797634
10.3109/00498254.2014.929192
10.1038/nrclinonc.2015.61
10.1016/j.semcancer.2020.08.009
10.1016/S0092-8674(00)81683-9
10.1002/ptr.2384
10.1016/S0140-6736(20)30165-3
10.3390/cancers13081892
10.1002/bmc.3037
10.1016/j.apjtm.2016.01.010
10.2217/nnm-2021-0329
10.1007/s12272-020-01265-8
10.3390/cancers10040101
ContentType Journal Article
Copyright The Author(s) 2023
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023. International Society for Chinese Medicine and BioMed Central Ltd.
International Society for Chinese Medicine and BioMed Central Ltd. 2023
Copyright_xml – notice: The Author(s) 2023
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023. International Society for Chinese Medicine and BioMed Central Ltd.
– notice: International Society for Chinese Medicine and BioMed Central Ltd. 2023
DBID C6C
AAYXX
CITATION
3V.
7T5
7TM
7X7
7XB
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GHDGH
H94
K9.
M0S
P64
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
RC3
7X8
5PM
DOA
DOI 10.1186/s13020-023-00822-9
DatabaseName Springer Nature OA Free Journals
CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Nucleic Acids Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Technology Research Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
AUTh Library subscriptions: ProQuest Central
ProQuest One
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Central
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Immunology Abstracts
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef






MEDLINE - Academic
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1749-8546
EndPage 28
ExternalDocumentID oai_doaj_org_article_b91188b18efb49939065c3cf4a93a4f5
PMC10518937
A766633200
10_1186_s13020_023_00822_9
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GrantInformation_xml – fundername: Zhejiang Traditional Chinese Medicine Administration
  grantid: 2015zz004
  funderid: http://dx.doi.org/10.13039/501100012175
– fundername: ;
  grantid: 2015zz004
GroupedDBID ---
0R~
29B
2WC
53G
5GY
5VS
6J9
6PF
7X7
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHSBF
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GS5
GX1
HMCUK
HYE
IAO
IHR
IHW
ITC
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PUEGO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TUS
UKHRP
UNMZH
WOQ
WOW
~8M
AAYXX
ALIPV
CITATION
PMFND
3V.
7T5
7TM
7XB
8FD
8FK
AZQEC
DWQXO
FR3
H94
K9.
P64
PKEHL
PQEST
PQUKI
RC3
7X8
5PM
ID FETCH-LOGICAL-c616t-d0e470a962dcd33a340a3031c150f606f31170732ced1676d6f08c46ec59247e3
IEDL.DBID 7X7
ISSN 1749-8546
IngestDate Wed Aug 27 01:30:00 EDT 2025
Thu Aug 21 18:36:07 EDT 2025
Thu Sep 04 18:05:03 EDT 2025
Sat Sep 20 14:21:48 EDT 2025
Tue Jun 17 22:21:40 EDT 2025
Tue Jun 10 21:17:31 EDT 2025
Thu May 22 21:20:39 EDT 2025
Tue Jul 01 01:00:04 EDT 2025
Thu Apr 24 22:53:34 EDT 2025
Sat Sep 06 07:29:34 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Epithelial-mesenchymal transition
Hallmarks of cancer
Cell growth
Breast cancer
Ginsenoside
Apoptosis
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c616t-d0e470a962dcd33a340a3031c150f606f31170732ced1676d6f08c46ec59247e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-7005-0842
OpenAccessLink https://www.proquest.com/docview/2877497687?pq-origsite=%requestingapplication%
PMID 37749560
PQID 2877497687
PQPubID 54985
PageCount 28
ParticipantIDs doaj_primary_oai_doaj_org_article_b91188b18efb49939065c3cf4a93a4f5
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10518937
proquest_miscellaneous_2869220810
proquest_journals_2877497687
gale_infotracmisc_A766633200
gale_infotracacademiconefile_A766633200
gale_healthsolutions_A766633200
crossref_primary_10_1186_s13020_023_00822_9
crossref_citationtrail_10_1186_s13020_023_00822_9
springer_journals_10_1186_s13020_023_00822_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-09-25
PublicationDateYYYYMMDD 2023-09-25
PublicationDate_xml – month: 09
  year: 2023
  text: 2023-09-25
  day: 25
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Chinese medicine
PublicationTitleAbbrev Chin Med
PublicationYear 2023
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References D Mayer (822_CR80) 2008; 114
SH Bae (822_CR42) 2014; 44
P Sarvari (822_CR107) 2022; 23
ZL Wang (822_CR31) 2021; 10
S Kim (822_CR30) 2021; 9
Y Jin (822_CR72) 2021; 22
Y Hong (822_CR63) 2019; 418
X Luo (822_CR149) 2021; 13
CN Baxevanis (822_CR140) 2021; 72
TN Seyfried (822_CR124) 2014; 35
J Lee (822_CR34) 2009; 122
T Qian (822_CR39) 2005; 816
P Jiang (822_CR32) 2014; 28
T Qian (822_CR36) 2010; 5
P Lu (822_CR50) 2008; 14
N-H Lee (822_CR45) 2012; 18
E Aksamitiene (822_CR85) 2012; 40
M Singh (822_CR152) 2018; 182
TK Yun (822_CR17) 2001; 16
DR Green (822_CR56) 2015; 7
J-X Miao (822_CR166) 2019; 132
H Mohammed (822_CR87) 2015; 523
SC Linn (822_CR23) 1997; 71
S-Y Kim (822_CR127) 2019; 42
MG Fradley (822_CR162) 2023; 6
V Zanuso (822_CR7) 2020; 6
SK Seo (822_CR44) 2014; 154
DTN Huynh (822_CR70) 2021; 13
B Zhou (822_CR51) 2016; 280
PLT My (822_CR79) 2020; 56
Y Zhu (822_CR147) 2022
RL Kan (822_CR106) 2022; 38
Y Zhang (822_CR10) 2019; 19
S Ren (822_CR46) 2022; 24
M Nakhjavani (822_CR177) 2019; 6
V Changizi (822_CR59) 2021; 46
MWL Teng (822_CR135) 2008; 84
M Pickup (822_CR84) 2013; 13
I Elia (822_CR125) 2021; 3
M Li (822_CR16) 2021; 12
A Kang (822_CR33) 2015; 7
H Beug (822_CR100) 2009; 138
B Zhang (822_CR130) 2022; 202
H Pang (822_CR40) 2001; 36
X-J Chen (822_CR48) 2016; 2016
H Greenlee (822_CR6) 2017; 67
Y Jin (822_CR174) 2020; 43
NR Maimela (822_CR139) 2019; 17
C Hu (822_CR119) 2021; 45
DJ Propper (822_CR145) 2022; 19
Y Zeng (822_CR67) 2020; 47
SS Menon (822_CR81) 2019; 491
Y Jin (822_CR71) 2022; 45
J Zhang (822_CR137) 2022; 43
L Ruan (822_CR15) 2022; 236
J Doherty (822_CR73) 2018; 20
D Hanahan (822_CR20) 2011; 144
D Zhang (822_CR121) 2021; 15
Y Zhan (822_CR26) 2021; 54
P Wang (822_CR49) 2020; 8
G Liu (822_CR167) 2022; 2022
RI Teleanu (822_CR93) 2020; 9
Y Li (822_CR77) 2021; 583
J Hou (822_CR103) 2020; 34
GS Wang (822_CR2) 2012; 6
M Younas (822_CR25) 2018; 8
M Hao (822_CR35) 2008; 3
BA Carneiro (822_CR55) 2020; 17
DA Lawson (822_CR96) 2015; 526
Z Wu (822_CR122) 2020; 22
D Mittal (822_CR141) 2014; 27
D Hanahan (822_CR12) 2022; 12
G Liu (822_CR168) 2021; 21
JH Cho (822_CR91) 2016; 7
A Tubbs (822_CR104) 2017; 168
LM Spring (822_CR88) 2020; 395
J Xia (822_CR148) 2022; 8
F Queiroga (822_CR172) 2023; 15
RL Siegel (822_CR1) 2022; 72
F Cardoso (822_CR5) 2019; 30
YH Guo (822_CR18) 2019; 19
WP Roos (822_CR54) 2016; 16
Y Feng (822_CR97) 2018; 5
H Kim (822_CR114) 2021; 11
D Yang (822_CR38) 2021; 35
K Barzaman (822_CR4) 2020; 84
P Wang (822_CR158) 2016; 6
ML Thomas (822_CR105) 2018; 10
L Ma (822_CR69) 2020; 103
MV Liberti (822_CR123) 2016; 41
L Tarantini (822_CR165) 2006; 13
L Yuan (822_CR9) 2021; 12
S Goossens (822_CR155) 2017; 1868
Q-G Gao (822_CR90) 2019; 43
M Nakhjavani (822_CR102) 2021; 14
D Ribatti (822_CR154) 2020; 13
RD York (822_CR86) 2000; 20
E Zhang (822_CR94) 2017; 38
D Hanahan (822_CR19) 2000; 100
YZ Xiang (822_CR27) 2008; 22
Y Chung (822_CR75) 2018; 22
L Dai (822_CR178) 2016; 4
J Hong (822_CR120) 2022; 46
MA Postow (822_CR146) 2015; 33
A Del Prete (822_CR136) 2022; 10
H Dillekas (822_CR151) 2019; 8
PA Henriksen (822_CR164) 2018; 104
H-G Kim (822_CR43) 2011; 49
J Xia (822_CR131) 2022; 20
M Yu (822_CR153) 2013; 339
JH Song (822_CR156) 2020; 15
Z Su (822_CR92) 2015; 14
H Gao (822_CR132) 2020; 124
D-H Kim (822_CR175) 2018; 42
Y Chu (822_CR65) 2020; 2020
A Ribas (822_CR134) 2015; 5
MA Feitelson (822_CR82) 2015; 35
Y Liu (822_CR61) 2020; 12
A Mohammadalipour (822_CR99) 2017; 10
SA Lee (822_CR47) 2012; 36
Z Yuan (822_CR58) 2017; 89
D Wang (822_CR142) 2015; 36
H Richly (822_CR110) 2010; 32
Z Luo (822_CR78) 2021; 32
H Masuda (822_CR83) 2012; 136
IW Kim (822_CR28) 2013; 37
TG Odle (822_CR161) 2014; 85
Y Zhang (822_CR95) 2016; 9
H-M Oh (822_CR57) 2022; 23
Z Chen (822_CR176) 2022; 12
NN Pavlova (822_CR126) 2022; 34
D Cardinale (822_CR163) 2020; 7
S Adams (822_CR143) 2019; 5
B Peng (822_CR160) 2019; 142
SJ Skuli (822_CR128) 2022; 15
YJ Kim (822_CR66) 2019; 14
CW Yun (822_CR74) 2018; 19
AM Jankowska (822_CR108) 2015; 15
S Liu (822_CR64) 2022; 36
K Zhang (822_CR159) 2016; 54
C Li (822_CR170) 2021; 16
J Hou (822_CR169) 2022; 55
F Nakasuka (822_CR109) 2020; 47
Q Zhao (822_CR41) 2010; 878
M Mohme (822_CR133) 2017; 14
Y Li (822_CR171) 2016; 7
G Dontu (822_CR21) 2004; 15
D Jeong (822_CR115) 2019; 47
NH Tung (822_CR29) 2009; 57
LJ Brown (822_CR111) 2022; 14
C Hong (822_CR150) 2020; 12
S Ravi (822_CR13) 2022; 14
D Molnar-Stanciu (822_CR14) 2012; 60
Z Duan (822_CR68) 2018; 499
K Peng (822_CR89) 2022; 54
X Li (822_CR52) 2015; 37
YS Wang (822_CR157) 2020; 10
F Hashemi (822_CR24) 2021; 14
F Lei (822_CR173) 2010; 35
Y Hong (822_CR62) 2019; 57
J Oh (822_CR101) 2019; 43
J-S Choi (822_CR53) 2013; 32
M Ebrahimi (822_CR22) 2010; 15
H Lee (822_CR118) 2018; 42
A Labani-Motlagh (822_CR138) 2020; 11
N Takebe (822_CR98) 2015; 12
Y Liu (822_CR60) 2018; 9
H Jeon (822_CR76) 2021; 44
G Sher (822_CR112) 2022; 83
J Ham (822_CR113) 2019; 43
J Ham (822_CR117) 2018; 46
D Micic (822_CR129) 2011; 10
BD Lehmann (822_CR3) 2011; 121
KH Lau (822_CR8) 2022; 23
YA Fouad (822_CR11) 2017; 7
K Li (822_CR37) 2005; 19
NP Restifo (822_CR144) 2012; 12
JE Park (822_CR116) 2022; 50
References_xml – volume: 7
  start-page: 1016
  issue: 5
  year: 2017
  ident: 822_CR11
  publication-title: Am J Cancer Res
– volume: 19
  start-page: 813
  issue: 6
  year: 2005
  ident: 822_CR37
  publication-title: Rapid Commun Mass Spectrom: RCM
  doi: 10.1002/rcm.1862
– volume: 17
  start-page: 1
  year: 2019
  ident: 822_CR139
  publication-title: Biotechnol J
– volume: 526
  start-page: 131
  issue: 7571
  year: 2015
  ident: 822_CR96
  publication-title: Nature
  doi: 10.1038/nature15260
– volume: 34
  start-page: 355
  issue: 3
  year: 2022
  ident: 822_CR126
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2022.01.007
– volume: 42
  start-page: 255
  issue: 3
  year: 2018
  ident: 822_CR175
  publication-title: J Ginseng Res
  doi: 10.1016/j.jgr.2017.04.011
– volume: 44
  start-page: 702
  issue: 7
  year: 2021
  ident: 822_CR76
  publication-title: Arch Pharm Res
  doi: 10.1007/s12272-021-01345-3
– volume: 21
  start-page: 1
  issue: 5
  year: 2021
  ident: 822_CR168
  publication-title: Exp Ther Med
– volume: 182
  start-page: 80
  year: 2018
  ident: 822_CR152
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2017.08.009
– volume: 33
  start-page: 1974
  issue: 17
  year: 2015
  ident: 822_CR146
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.59.4358
– volume: 5
  start-page: 77
  issue: 2
  year: 2018
  ident: 822_CR97
  publication-title: Genes Dis
  doi: 10.1016/j.gendis.2018.05.001
– volume: 523
  start-page: 313
  issue: 7560
  year: 2015
  ident: 822_CR87
  publication-title: Nature
  doi: 10.1038/nature14583
– volume: 35
  start-page: 2221
  issue: 17
  year: 2010
  ident: 822_CR173
  publication-title: Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi =China J Chin Mater Med
– volume: 18
  start-page: 1061
  issue: 11
  year: 2012
  ident: 822_CR45
  publication-title: J Altern Complement Med
  doi: 10.1089/acm.2011.0591
– volume: 54
  start-page: 81
  issue: 1
  year: 2021
  ident: 822_CR26
  publication-title: Allelopathy J
  doi: 10.26651/allelo.j/2021-54-1-1350
– volume: 7
  start-page: 26
  year: 2020
  ident: 822_CR163
  publication-title: Front Cardiovasc Med
  doi: 10.3389/fcvm.2020.00026
– volume: 55
  start-page: e13246
  issue: 6
  year: 2022
  ident: 822_CR169
  publication-title: Cell Prolif
  doi: 10.1111/cpr.13246
– volume: 23
  start-page: 9521
  issue: 17
  year: 2022
  ident: 822_CR107
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms23179521
– volume: 142
  start-page: 1
  year: 2019
  ident: 822_CR160
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2019.02.003
– volume: 16
  start-page: S6
  issue: Suppl
  year: 2001
  ident: 822_CR17
  publication-title: J Korean Med Sci
  doi: 10.3346/jkms.2001.16.S.S6
– volume: 12
  start-page: 801662
  year: 2021
  ident: 822_CR9
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2021.801662
– volume: 7
  start-page: a006080
  issue: 12
  year: 2015
  ident: 822_CR56
  publication-title: Cold Spring Harbor Perspect Biol
  doi: 10.1101/cshperspect.a006080
– volume: 22
  start-page: 382
  issue: 6
  year: 2018
  ident: 822_CR75
  publication-title: Anim Cells Syst
  doi: 10.1080/19768354.2018.1545696
– volume: 12
  start-page: 246
  issue: 1
  year: 2020
  ident: 822_CR61
  publication-title: Nutrients
  doi: 10.3390/nu12010246
– volume: 47
  start-page: 1407
  issue: 10
  year: 2020
  ident: 822_CR109
  publication-title: Cancer Chemother
– volume: 43
  start-page: 523
  issue: 7
  year: 2022
  ident: 822_CR137
  publication-title: Trends Immunol
  doi: 10.1016/j.it.2022.04.010
– volume: 12
  start-page: 129
  issue: 1
  year: 2020
  ident: 822_CR150
  publication-title: Nanomicro Lett
– volume: 19
  start-page: 1179
  issue: 5
  year: 2019
  ident: 822_CR10
  publication-title: Phytochem Rev
  doi: 10.1007/s11101-019-09628-w
– volume: 168
  start-page: 644
  issue: 4
  year: 2017
  ident: 822_CR104
  publication-title: Cell
  doi: 10.1016/j.cell.2017.01.002
– volume: 45
  start-page: 734
  issue: 6
  year: 2021
  ident: 822_CR119
  publication-title: J Ginseng Res
  doi: 10.1016/j.jgr.2021.05.004
– volume: 57
  start-page: 1412
  issue: 12
  year: 2009
  ident: 822_CR29
  publication-title: Chem Pharm Bull
  doi: 10.1248/cpb.57.1412
– volume: 12
  start-page: 269
  issue: 4
  year: 2012
  ident: 822_CR144
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri3191
– volume: 24
  start-page: 8302
  issue: 21
  year: 2022
  ident: 822_CR46
  publication-title: Green Chem
  doi: 10.1039/D2GC02639B
– volume: 14
  start-page: e24803
  issue: 5
  year: 2022
  ident: 822_CR13
  publication-title: Cureus
– volume: 71
  start-page: 787
  issue: 5
  year: 1997
  ident: 822_CR23
  publication-title: Int J Cancer
  doi: 10.1002/(SICI)1097-0215(19970529)71:5<787::AID-IJC16>3.0.CO;2-5
– volume: 878
  start-page: 2266
  issue: 24
  year: 2010
  ident: 822_CR41
  publication-title: J Chromatogr B-Anal Technol Biomed Life Sci
  doi: 10.1016/j.jchromb.2010.06.019
– volume: 5
  start-page: 915
  issue: 9
  year: 2015
  ident: 822_CR134
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-15-0563
– volume: 339
  start-page: 580
  issue: 6119
  year: 2013
  ident: 822_CR153
  publication-title: Science
  doi: 10.1126/science.1228522
– volume: 8
  start-page: e9281
  year: 2020
  ident: 822_CR49
  publication-title: PeerJ
  doi: 10.7717/peerj.9281
– volume: 36
  start-page: e22945
  issue: 1
  year: 2022
  ident: 822_CR64
  publication-title: J Biochem Mol Toxicol
  doi: 10.1002/jbt.22945
– volume: 37
  start-page: 124
  issue: 1
  year: 2013
  ident: 822_CR28
  publication-title: J Ginseng Res
  doi: 10.5142/jgr.2013.37.124
– volume: 60
  start-page: 254
  issue: 4
  year: 2012
  ident: 822_CR14
  publication-title: Pathol Biol
  doi: 10.1016/j.patbio.2012.05.012
– volume: 136
  start-page: 331
  issue: 2
  year: 2012
  ident: 822_CR83
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-012-2289-9
– volume: 22
  start-page: 10458
  issue: 19
  year: 2021
  ident: 822_CR72
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms221910458
– volume: 36
  start-page: 1085
  issue: 10
  year: 2015
  ident: 822_CR142
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgv123
– volume: 13
  start-page: 100773
  issue: 6
  year: 2020
  ident: 822_CR154
  publication-title: Transl Oncol
  doi: 10.1016/j.tranon.2020.100773
– volume: 8
  start-page: 29714
  issue: 52
  year: 2018
  ident: 822_CR25
  publication-title: RSC Adv
  doi: 10.1039/C8RA04879G
– volume: 104
  start-page: 971
  issue: 12
  year: 2018
  ident: 822_CR164
  publication-title: Heart
  doi: 10.1136/heartjnl-2017-312103
– volume: 10
  start-page: 1068720
  year: 2022
  ident: 822_CR136
  publication-title: Front Cell Dev Biol
  doi: 10.3389/fcell.2022.1068720
– volume: 84
  start-page: 988
  issue: 4
  year: 2008
  ident: 822_CR135
  publication-title: J Leukoc Biol
  doi: 10.1189/jlb.1107774
– volume: 46
  start-page: 291
  issue: 4
  year: 2021
  ident: 822_CR59
  publication-title: Iran J Med Sci
– volume: 2020
  start-page: 8886955
  year: 2020
  ident: 822_CR65
  publication-title: Evid Based Compl Alternat Med
  doi: 10.1155/2020/8886955
– volume: 50
  start-page: 1703
  issue: 6
  year: 2022
  ident: 822_CR116
  publication-title: Am J Chin Med
  doi: 10.1142/S0192415X22500720
– volume: 12
  start-page: 853981
  year: 2022
  ident: 822_CR176
  publication-title: Front Cell Infect Microbiol
  doi: 10.3389/fcimb.2022.853981
– volume: 15
  start-page: 626
  issue: 5
  year: 2022
  ident: 822_CR128
  publication-title: Pharmaceuticals
  doi: 10.3390/ph15050626
– volume: 20
  start-page: 1110
  issue: 10
  year: 2018
  ident: 822_CR73
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-018-0201-5
– volume: 6
  start-page: FSO617
  issue: 9
  year: 2020
  ident: 822_CR7
  publication-title: Future Sci OA
  doi: 10.2144/fsoa-2020-0076
– volume: 583
  start-page: 184
  year: 2021
  ident: 822_CR77
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2021.10.067
– volume: 8
  start-page: eabj1262
  issue: 6
  year: 2022
  ident: 822_CR148
  publication-title: Sci Adv
  doi: 10.1126/sciadv.abj1262
– volume: 20
  start-page: 414
  issue: 1
  year: 2022
  ident: 822_CR131
  publication-title: J Nanobiotechnology
  doi: 10.1186/s12951-022-01623-2
– volume: 30
  start-page: 1194
  issue: 8
  year: 2019
  ident: 822_CR5
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdz173
– volume: 114
  start-page: 38
  issue: 1
  year: 2008
  ident: 822_CR80
  publication-title: Arch Physiol Biochem
  doi: 10.1080/13813450801900645
– volume: 13
  start-page: 54S
  issue: 5 Suppl 1
  year: 2006
  ident: 822_CR165
  publication-title: G Ital Cardiol
– volume: 144
  start-page: 646
  issue: 5
  year: 2011
  ident: 822_CR20
  publication-title: Cell
  doi: 10.1016/j.cell.2011.02.013
– volume: 46
  start-page: 481
  issue: 3
  year: 2022
  ident: 822_CR120
  publication-title: J Ginseng Res
  doi: 10.1016/j.jgr.2021.11.004
– volume: 6
  start-page: 779
  issue: 4
  year: 2012
  ident: 822_CR2
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2012.981
– year: 2022
  ident: 822_CR147
  publication-title: J Adv Res
  doi: 10.1016/j.jare.2022.09.007
– volume: 6
  start-page: e2254677
  issue: 2
  year: 2023
  ident: 822_CR162
  publication-title: JAMA Netw Open
  doi: 10.1001/jamanetworkopen.2022.54677
– volume: 32
  start-page: 195103
  issue: 19
  year: 2021
  ident: 822_CR78
  publication-title: Nanotechnology
  doi: 10.1088/1361-6528/abe1f0
– volume: 84
  start-page: 106535
  year: 2020
  ident: 822_CR4
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2020.106535
– volume: 14
  start-page: 33
  issue: 1
  year: 2008
  ident: 822_CR50
  publication-title: Chin J Integr Med
  doi: 10.1007/s11655-007-9002-6
– volume: 122
  start-page: 143
  issue: 1
  year: 2009
  ident: 822_CR34
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2008.12.012
– volume: 32
  start-page: 669
  issue: 8
  year: 2010
  ident: 822_CR110
  publication-title: BioEssays
  doi: 10.1002/bies.201000016
– volume: 15
  start-page: 1335
  issue: 4
  year: 2023
  ident: 822_CR172
  publication-title: Cancers
  doi: 10.3390/cancers15041335
– volume: 9
  start-page: 1344
  issue: 8
  year: 2021
  ident: 822_CR30
  publication-title: Processes
  doi: 10.3390/pr9081344
– volume: 14
  start-page: 8195
  year: 2019
  ident: 822_CR66
  publication-title: Int J Nanomed
  doi: 10.2147/IJN.S221328
– volume: 72
  start-page: 7
  issue: 1
  year: 2022
  ident: 822_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21708
– volume: 418
  start-page: 22
  year: 2019
  ident: 822_CR63
  publication-title: Toxicology
  doi: 10.1016/j.tox.2019.02.010
– volume: 34
  start-page: 1659
  issue: 7
  year: 2020
  ident: 822_CR103
  publication-title: Phytother Res
  doi: 10.1002/ptr.6636
– volume: 491
  start-page: 39
  year: 2019
  ident: 822_CR81
  publication-title: Clin Chim Acta
  doi: 10.1016/j.cca.2019.01.011
– volume: 42
  start-page: 140
  issue: 2
  year: 2019
  ident: 822_CR127
  publication-title: Arch Pharmacal Res
  doi: 10.1007/s12272-019-01115-2
– volume: 40
  start-page: 139
  year: 2012
  ident: 822_CR85
  publication-title: Biochem Soc Trans
  doi: 10.1042/BST20110609
– volume: 22
  start-page: 631
  issue: 5
  year: 2020
  ident: 822_CR122
  publication-title: Clin Transl Oncol
  doi: 10.1007/s12094-019-02187-8
– volume: 280
  start-page: 630
  issue: 2
  year: 2016
  ident: 822_CR51
  publication-title: Radiology
  doi: 10.1148/radiol.2016150719
– volume: 6
  start-page: 33709
  year: 2016
  ident: 822_CR158
  publication-title: Sci Rep
  doi: 10.1038/srep33709
– volume: 499
  start-page: 482
  issue: 3
  year: 2018
  ident: 822_CR68
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2018.03.174
– volume: 6
  start-page: 17
  issue: 1
  year: 2019
  ident: 822_CR177
  publication-title: Medicines
  doi: 10.3390/medicines6010017
– volume: 56
  start-page: 1687
  issue: 10
  year: 2020
  ident: 822_CR79
  publication-title: Sep Sci Technol
– volume: 15
  start-page: 1325
  issue: 10
  year: 2015
  ident: 822_CR108
  publication-title: Expert Rev Mol Diagn
  doi: 10.1586/14737159.2015.1084229
– volume: 27
  start-page: 16
  year: 2014
  ident: 822_CR141
  publication-title: Curr Opin Immunol
  doi: 10.1016/j.coi.2014.01.004
– volume: 816
  start-page: 223
  issue: 1–2
  year: 2005
  ident: 822_CR39
  publication-title: B Anal Technol Biomed Life Sci
  doi: 10.1016/j.jchromb.2004.11.036
– volume: 15
  start-page: e0240533
  issue: 10
  year: 2020
  ident: 822_CR156
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0240533
– volume: 67
  start-page: 194
  issue: 3
  year: 2017
  ident: 822_CR6
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21397
– volume: 41
  start-page: 211
  issue: 3
  year: 2016
  ident: 822_CR123
  publication-title: Trends Biochem Sci
  doi: 10.1016/j.tibs.2015.12.001
– volume: 19
  start-page: 2334
  issue: 25
  year: 2019
  ident: 822_CR18
  publication-title: Curr Top Med Chem
  doi: 10.2174/1568026619666191018100848
– volume: 14
  start-page: 1093
  issue: 6
  year: 2021
  ident: 822_CR24
  publication-title: Curr Mol Pharmacol
  doi: 10.2174/1874467214666210120153348
– volume: 10
  start-page: 5
  issue: 1
  year: 2011
  ident: 822_CR129
  publication-title: Horm-Int J Endocrinol Metab
– volume: 15
  start-page: 193
  issue: 5
  year: 2004
  ident: 822_CR21
  publication-title: Trends Endocrinol Metab
  doi: 10.1016/j.tem.2004.05.011
– volume: 10
  start-page: 669
  issue: 6
  year: 2021
  ident: 822_CR31
  publication-title: Clin Pharmacol Drug Dev
  doi: 10.1002/cpdd.877
– volume: 23
  start-page: 9077
  issue: 16
  year: 2022
  ident: 822_CR57
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms23169077
– volume: 19
  start-page: 237
  issue: 4
  year: 2022
  ident: 822_CR145
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-021-00588-9
– volume: 9
  start-page: 84
  issue: 1
  year: 2020
  ident: 822_CR93
  publication-title: J Clin Med
  doi: 10.3390/jcm9010084
– volume: 2016
  start-page: 5738694
  year: 2016
  ident: 822_CR48
  publication-title: Evid-Based Compl Altern Med
  doi: 10.1155/2016/5738694
– volume: 121
  start-page: 2750
  issue: 7
  year: 2011
  ident: 822_CR3
  publication-title: J Clin Invest
  doi: 10.1172/JCI45014
– volume: 16
  start-page: 20
  issue: 1
  year: 2016
  ident: 822_CR54
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2015.2
– volume: 54
  start-page: 561
  issue: 4
  year: 2016
  ident: 822_CR159
  publication-title: Pharm Biol
  doi: 10.3109/13880209.2015.1101142
– volume: 17
  start-page: 395
  issue: 7
  year: 2020
  ident: 822_CR55
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-020-0341-y
– volume: 46
  start-page: 1333
  issue: 06
  year: 2018
  ident: 822_CR117
  publication-title: Am J Chin Med
  doi: 10.1142/S0192415X18500702
– volume: 11
  start-page: 118
  issue: 1
  year: 2021
  ident: 822_CR114
  publication-title: Biomolecules
  doi: 10.3390/biom11010118
– volume: 1868
  start-page: 584
  issue: 2
  year: 2017
  ident: 822_CR155
  publication-title: Biochim Biophys Acta-Rev Cancer
  doi: 10.1016/j.bbcan.2017.06.006
– volume: 15
  start-page: 299
  issue: 6
  year: 2010
  ident: 822_CR22
  publication-title: J Res Med Sci
– volume: 9
  start-page: 5513
  issue: 11
  year: 2018
  ident: 822_CR60
  publication-title: Food Funct
  doi: 10.1039/C8FO01122B
– volume: 12
  start-page: 31
  issue: 1
  year: 2022
  ident: 822_CR12
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-21-1059
– volume: 154
  start-page: 753
  issue: 3
  year: 2014
  ident: 822_CR44
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2014.04.051
– volume: 15
  start-page: 178
  issue: 2
  year: 2021
  ident: 822_CR121
  publication-title: Front Med
  doi: 10.1007/s11684-020-0793-6
– volume: 5
  start-page: 1205
  issue: 8
  year: 2019
  ident: 822_CR143
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2018.7147
– volume: 14
  start-page: 155
  issue: 3
  year: 2017
  ident: 822_CR133
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2016.144
– volume: 3
  start-page: 21
  issue: 1
  year: 2021
  ident: 822_CR125
  publication-title: Nat Metab
  doi: 10.1038/s42255-020-00317-z
– volume: 72
  start-page: 76
  year: 2021
  ident: 822_CR140
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2019.12.018
– volume: 124
  start-page: 109891
  year: 2020
  ident: 822_CR132
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2020.109891
– volume: 14
  start-page: 633
  issue: 7
  year: 2021
  ident: 822_CR102
  publication-title: Pharmaceuticals
  doi: 10.3390/ph14070633
– volume: 14
  start-page: 1
  year: 2015
  ident: 822_CR92
  publication-title: Mol Cancer
– volume: 32
  start-page: 1227
  issue: 6
  year: 2013
  ident: 822_CR53
  publication-title: Int J Mol Med
  doi: 10.3892/ijmm.2013.1519
– volume: 43
  start-page: 625
  issue: 4
  year: 2019
  ident: 822_CR113
  publication-title: J Ginseng Res
  doi: 10.1016/j.jgr.2019.02.004
– volume: 2022
  start-page: 1
  year: 2022
  ident: 822_CR167
  publication-title: Biomed Res Int
– volume: 13
  start-page: 17177
  issue: 13
  year: 2021
  ident: 822_CR149
  publication-title: Aging
  doi: 10.18632/aging.203131
– volume: 7
  start-page: 70535
  issue: 43
  year: 2016
  ident: 822_CR171
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.12059
– volume: 10
  start-page: 235
  issue: 3
  year: 2017
  ident: 822_CR99
  publication-title: Cell Mol Bioeng
  doi: 10.1007/s12195-017-0485-8
– volume: 23
  start-page: 2288
  issue: 4
  year: 2022
  ident: 822_CR8
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms23042288
– volume: 138
  start-page: 623
  issue: 4
  year: 2009
  ident: 822_CR100
  publication-title: Cell
  doi: 10.1016/j.cell.2009.08.007
– volume: 14
  start-page: 474
  issue: 3
  year: 2022
  ident: 822_CR111
  publication-title: Cancers
  doi: 10.3390/cancers14030474
– volume: 11
  start-page: 940
  year: 2020
  ident: 822_CR138
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2020.00940
– volume: 42
  start-page: 455
  issue: 4
  year: 2018
  ident: 822_CR118
  publication-title: J Ginseng Res
  doi: 10.1016/j.jgr.2017.05.003
– volume: 202
  start-page: 115101
  year: 2022
  ident: 822_CR130
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2022.115101
– volume: 45
  start-page: 174
  issue: 3
  year: 2022
  ident: 822_CR71
  publication-title: Arch Pharm Res
  doi: 10.1007/s12272-022-01377-3
– volume: 35
  start-page: e9083
  issue: 11
  year: 2021
  ident: 822_CR38
  publication-title: Rapid Commun Mass Spectrom
  doi: 10.1002/rcm.9083
– volume: 89
  start-page: 227
  year: 2017
  ident: 822_CR58
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2017.02.038
– volume: 13
  start-page: 788
  issue: 11
  year: 2013
  ident: 822_CR84
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3603
– volume: 132
  start-page: 2724
  issue: 22
  year: 2019
  ident: 822_CR166
  publication-title: Chin Med J
  doi: 10.1097/CM9.0000000000000498
– volume: 57
  start-page: 255
  year: 2019
  ident: 822_CR62
  publication-title: J Funct Foods
  doi: 10.1016/j.jff.2019.04.019
– volume: 38
  start-page: 182
  issue: 2
  year: 2022
  ident: 822_CR106
  publication-title: Trends Genet
  doi: 10.1016/j.tig.2021.06.014
– volume: 37
  start-page: 2445
  issue: 16
  year: 2015
  ident: 822_CR52
  publication-title: Hebei Med J
– volume: 7
  start-page: 6173
  issue: 15
  year: 2015
  ident: 822_CR33
  publication-title: Anal Methods
  doi: 10.1039/C5AY01365H
– volume: 7
  start-page: 35144
  issue: 23
  year: 2016
  ident: 822_CR91
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.9059
– volume: 236
  start-page: 153956
  year: 2022
  ident: 822_CR15
  publication-title: Pathol Res Pract
  doi: 10.1016/j.prp.2022.153956
– volume: 20
  start-page: 8069
  issue: 21
  year: 2000
  ident: 822_CR86
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.20.21.8069-8083.2000
– volume: 10
  start-page: 528
  issue: 4
  year: 2020
  ident: 822_CR157
  publication-title: Biomolecules
  doi: 10.3390/biom10040528
– volume: 19
  start-page: 3466
  issue: 11
  year: 2018
  ident: 822_CR74
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms19113466
– volume: 43
  start-page: 527
  issue: 4
  year: 2019
  ident: 822_CR90
  publication-title: J Ginseng Res
  doi: 10.1016/j.jgr.2018.03.004
– volume: 5
  start-page: 19
  year: 2010
  ident: 822_CR36
  publication-title: Chin Med
  doi: 10.1186/1749-8546-5-19
– volume: 49
  start-page: 2229
  issue: 9
  year: 2011
  ident: 822_CR43
  publication-title: Food Chem Toxicol
  doi: 10.1016/j.fct.2011.06.020
– volume: 35
  start-page: S25
  year: 2015
  ident: 822_CR82
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2015.02.006
– volume: 54
  start-page: 647
  issue: 5
  year: 2022
  ident: 822_CR89
  publication-title: Acta Biochim Biophys Sin
  doi: 10.3724/abbs.2022039
– volume: 47
  start-page: 99
  issue: 1
  year: 2020
  ident: 822_CR67
  publication-title: Clin Exp Obstet Gynecol
– volume: 38
  start-page: 359
  issue: 1
  year: 2017
  ident: 822_CR94
  publication-title: Oncol Rep
  doi: 10.3892/or.2017.5652
– volume: 43
  start-page: 421
  issue: 3
  year: 2019
  ident: 822_CR101
  publication-title: J Ginseng Res
  doi: 10.1016/j.jgr.2018.05.004
– volume: 8
  start-page: 5574
  issue: 12
  year: 2019
  ident: 822_CR151
  publication-title: Cancer Med
  doi: 10.1002/cam4.2474
– volume: 3
  start-page: e2697
  issue: 7
  year: 2008
  ident: 822_CR35
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0002697
– volume: 85
  start-page: 297M
  issue: 3
  year: 2014
  ident: 822_CR161
  publication-title: Radiol Technol
– volume: 36
  start-page: 102
  issue: 1
  year: 2012
  ident: 822_CR47
  publication-title: J Ginseng Res
  doi: 10.5142/jgr.2012.36.1.102
– volume: 47
  start-page: 1643
  issue: 7
  year: 2019
  ident: 822_CR115
  publication-title: Am J Chin Med
  doi: 10.1142/S0192415X19500848
– volume: 35
  start-page: 515
  issue: 3
  year: 2014
  ident: 822_CR124
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgt480
– volume: 4
  start-page: 529
  issue: 3
  year: 2016
  ident: 822_CR178
  publication-title: J Mater Chem B
  doi: 10.1039/C5TB02305J
– volume: 12
  start-page: 797634
  year: 2021
  ident: 822_CR16
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2021.797634
– volume: 44
  start-page: 1099
  issue: 12
  year: 2014
  ident: 822_CR42
  publication-title: Xenobiotica
  doi: 10.3109/00498254.2014.929192
– volume: 103
  year: 2020
  ident: 822_CR69
  publication-title: Bioorg Chem
– volume: 12
  start-page: 445
  issue: 8
  year: 2015
  ident: 822_CR98
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2015.61
– volume: 83
  start-page: 152
  year: 2022
  ident: 822_CR112
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2020.08.009
– volume: 100
  start-page: 57
  issue: 1
  year: 2000
  ident: 822_CR19
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)81683-9
– volume: 22
  start-page: 851
  issue: 7
  year: 2008
  ident: 822_CR27
  publication-title: Phytother Res
  doi: 10.1002/ptr.2384
– volume: 395
  start-page: 817
  issue: 10226
  year: 2020
  ident: 822_CR88
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30165-3
– volume: 13
  start-page: 1892
  issue: 8
  year: 2021
  ident: 822_CR70
  publication-title: Cancers
  doi: 10.3390/cancers13081892
– volume: 28
  start-page: 419
  issue: 3
  year: 2014
  ident: 822_CR32
  publication-title: Biomed Chromatogr
  doi: 10.1002/bmc.3037
– volume: 36
  start-page: 170
  issue: 3
  year: 2001
  ident: 822_CR40
  publication-title: Yao xue xue bao = Acta Pharm Sin
– volume: 9
  start-page: 180
  issue: 2
  year: 2016
  ident: 822_CR95
  publication-title: Asian Pac J Trop Med
  doi: 10.1016/j.apjtm.2016.01.010
– volume: 16
  start-page: 2587
  issue: 29
  year: 2021
  ident: 822_CR170
  publication-title: Nanomedicine
  doi: 10.2217/nnm-2021-0329
– volume: 43
  start-page: 773
  issue: 8
  year: 2020
  ident: 822_CR174
  publication-title: Arch Pharmacal Res
  doi: 10.1007/s12272-020-01265-8
– volume: 10
  start-page: 101
  issue: 4
  year: 2018
  ident: 822_CR105
  publication-title: Cancers
  doi: 10.3390/cancers10040101
SSID ssj0053538
Score 2.3615172
SecondaryResourceType review_article
Snippet In 2021, breast cancer accounted for a substantial proportion of cancer cases and represented the second leading cause of cancer deaths among women worldwide....
Abstract In 2021, breast cancer accounted for a substantial proportion of cancer cases and represented the second leading cause of cancer deaths among women...
SourceID doaj
pubmedcentral
proquest
gale
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 1
SubjectTerms Acupuncture
Angiogenesis
Apoptosis
Bone density
Breast cancer
Cancer
Cancer cells
Cancer therapies
Care and treatment
Cell death
Cell growth
Chemotherapy
Clinical medicine
Complementary & Alternative Medicine
Development and progression
Drugs
Epithelial-mesenchymal transition
Genetic aspects
Ginsenoside
Ginsenosides
Hallmarks of cancer
Health aspects
Herbal medicine
Inflammation
Medical research
Medicine
Medicine & Public Health
Metastasis
Oncology, Experimental
Pathogenesis
Patients
Physiological aspects
Quality of life
Review
Structure-function relationships
Toxicity
Traditional Chinese Medicine
Tumor cells
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1Lb9YwLEI7IC6IpygMCBISB4jWJmmachuIMSGNE5N2i1I3EZ_G2ulrx-_HTtsPygRcuDZO2voR24kfjL1salWDllpIH0HoIEthQ4wi5kp628o8AiUnn3w2x6f601l59kurL4oJm8oDT4g7aFAarW0KXKFB6xxddFOCgqh9rbyOqXopqrHFmZr24FKhHC8pMtYcDHQ9lwvUTyKVOBf1Sg2lav3X9-TrcZK_XZYmHXR0h92ejUd-OH30XXYjdPfYzZP5evw-O_-4oaPinlpwDm95SurFhTgaeRzV1QY4tU658NvzgfeRA1F8y-nsfuBjzymuMnwPCfwSCdAPgcBSLDot01AA-zhPe8BOjz58eX8s5m4KAkxhRtHmQVe5r41soVXKK5171F8FoEkY0Y2JiprQVEpCaAtTmdbE3II2AUr00aqgHrK9ru_CI8YLHWNDplfwUlswvgZVNKpsoDTRFnnGigW5DuZS49Tx4ptLLoc1biKIQ4K4RBBXZ-z1bs7lVGjjr9DviGY7SCqSnR4g67iZddy_WCdjz4nibso43Ym6O6zQp1MK94-MvUoQJOz4A-DnnAVEA5XNWkHuryBRSGE9vHCVmzeJwaGzWmk0B22VsRe7YZpJgW9d6K8IxtQSGZyQalfcuPr39Ui3-ZoKhaPtXJA9mrE3C-P-fPufkfv4fyD3Cbslk7zVQpb7bG_cXoWnaL-NzbMkqj8AMUA_MA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1da9UwNOgE8UX8xOrUCIIPGmw-mia-zYtzCPPJwd5CmiZ42WzHbefv95zc9mqdCr42Jy093yc5H4S8bKy0QQnFhE-BqSgqZmJKLJVSeNOKMgUsTj7-rI9O1KfT6nRqk4O1ML_e33Oj3w54sVYysCwsNydn9jq5UcFDTN9b6dWsdSsJkjsXxfxx38Lw5P78V7Xw1czI365Hs9U5vENuT-4iPdjS9y65Frt75ObxdCF-n5x9XOPhcI9DN4d3NJfxwosouHUUDNQ6UByW8s1vzgbaJxqQxhuKp_UDHXuKmZTxe8zgF4DyfogIlrPP8TUNpqyP07YH5OTww5fVEZvmJ7CguR5ZW0ZVl95q0YZWSi9V6cFi8QBOYILAJUkcO1NLEWLLda1bnUoTlI6hgqisjvIh2ev6Lj4ilKuUGnS2ohfKBO1tkLyRVRMqnQwvC8Jn5LowNRfHGRfnLgcZRrstQRwQxGWCOFuQ17s9F9vWGv-Efo8020FiW-z8ALjFTVLmGlDdxjQc2K2BUE5acLCCDEl5K71KVUGeI8XdtsZ0J9zuoIYoTkrQGAV5lSFQvOEHgp-qFAAN2ChrAbm_gASxDMvlmavcpBYGB-FprcABNHVBXuyWcSemunWxv0QYbYUoM1LNghsX_75c6dZfc2tw8JY5eqAFeTMz7s-v_x25j_8P_Am5JbJkWSaqfbI3bi7jU_DNxuZZFsof654vkw
  priority: 102
  providerName: Springer Nature
Title Ginsenosides: changing the basic hallmarks of cancer cells to achieve the purpose of treating breast cancer
URI https://link.springer.com/article/10.1186/s13020-023-00822-9
https://www.proquest.com/docview/2877497687
https://www.proquest.com/docview/2869220810
https://pubmed.ncbi.nlm.nih.gov/PMC10518937
https://doaj.org/article/b91188b18efb49939065c3cf4a93a4f5
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: BioMedCentral
  customDbUrl:
  eissn: 1749-8546
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053538
  issn: 1749-8546
  databaseCode: RBZ
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1749-8546
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053538
  issn: 1749-8546
  databaseCode: DOA
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1749-8546
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053538
  issn: 1749-8546
  databaseCode: ABDBF
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1749-8546
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053538
  issn: 1749-8546
  databaseCode: DIK
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1749-8546
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053538
  issn: 1749-8546
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1749-8546
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053538
  issn: 1749-8546
  databaseCode: RPM
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1749-8546
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053538
  issn: 1749-8546
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1749-8546
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053538
  issn: 1749-8546
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVAVX
  databaseName: Springer Nature HAS Fully OA
  customDbUrl:
  eissn: 1749-8546
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053538
  issn: 1749-8546
  databaseCode: AAJSJ
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: https://www.springernature.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: Springer Nature OA Free Journals
  customDbUrl:
  eissn: 1749-8546
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053538
  issn: 1749-8546
  databaseCode: C6C
  dateStart: 20061201
  isFulltext: true
  titleUrlDefault: http://www.springeropen.com/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgkxAviE8RGCVISDyAtcR2HJsX1FUbU6VNCJi0N8tx7FENmtJ0_P3cuW6nMLGnSsk5TXxfv7PPd4S8bTTXTjBBmQ2OCs8qqnwINBScWdWyIjg8nHxyKo_PxPS8Ok8Lbn1Kq9zYxGio287hGvk-IPtagO9U9afFb4pdo3B3NbXQuEt2S4AqKNX1-TbgqngVO1kD6NZUVUJuDs0oud_jhl1BwWPRWPSc6oFjivX7b1rpm5mT_2yfRq909JA8SHAyH6_5_4jc8fPH5N5J2jB_Qi4_z3DxuMOmnP3HPB7zhQflAPtycGAzl2MzlV92ednnXcgdysAyx9X8Pl91OWZa-j8-ki-AJV3vkSxmp-NjGkxpX6VhT8nZ0eH3yTFN_RWok6Vc0bbwoi6slqx1LeeWi8KCRysdgMQAgU3g2Jam5sz5tpS1bGUolBPSuwqittrzZ2Rn3s39c5KXIoQGwZi3TCgnrXa8bHjVuEoGVRYZKTeTa1wqPo49MH6aGIQoadYMMcAQExlidEbeb8cs1qU3bqU-QJ5tKbFsdrzQLS9M0kLTgGlXqilBHBsI9bgGAOa4C8JqbkWoMvIaOW7WZ1C3ym_GNUR5nINFyci7SIHqDx_gbDrFANOAhbQGlHsDSlBbN7y9kSqTzEZvroU8I2-2t3EkpsLNfXeFNFIzVsRJVQNpHHz78M589iOWDgc0XSJCzciHjeBe__v_J_fF7S_7ktxnUZM0ZdUe2Vktr_wrwGqrZhQVckR2x-Pptyn8HhyefvkKVydyMorrH38B0ws95w
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4ikChRoJxAGsJrbjOEgIlUfZ0m5PrbQ3N3FsWBU2y2YL4k_xG5lxkq1CRW-9rsfOxjOe-SaeByHPylzkVnLJeOEtk46nTDvvmY8FL3TFY28xOXl8oEZH8vMknayRP30uDIZV9joxKOqqtviNfAuQfSbBdurs7fwHw65ReLvat9BoxWLP_f4FLlvzZvcD8Pc55zsfD9-PWNdVgFmVqCWrYiezuMgVr2wlRCFkXIAeTyxAIw9w3gtsxpIJbl2VqExVysfaSuVsCr5K5gSse4VclSKWWKs_m6wcvFSkoXM2gPyc6VSqPklHq60GLwhjBhaShSLrLB8YwtAv4LxVOB-p-c91bbCCO7fIzQ6-0u1W3m6TNTe7Q66Nuwv6u-Tk0xQ_VtfYBLR5TUNaMSxEAWZSMJhTS7F5y_dicdLQ2lOLMregeHvQ0GVNMbLT_XSBfA4iUDcOyUI0PC5TYgj9spt2jxxdys7fJ-uzeuYeEJpI70sEf67gUltV5FYkpUhLmyqvkzgiSb-5xnbFzrHnxjcTnB6tTMsQAwwxgSEmj8jL1Zx5W-rjQup3yLMVJZbpDj_Uiy-mO_WmBFOidZmA-JfgWoocAJ8V1ssiF4X0aUQ2keOmzXldKRuznYFXKQRosIi8CBSobuAFbNFlTcA2YOGuAeXGgBLUhB0O91JlOjXVmLNDFZGnq2GciaF3M1efIo3KOY_DpuqBNA7efTgym34NpcoBvSeIiCPyqhfcs6f_f3MfXvxnN8n10eF43-zvHuw9Ijd4OFU54-kGWV8uTt1jwInL8kk4nJQcX7Y2-AsnTnPj
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELaglSouiKcILTRISBwgamI7js1teSxloRUSVOrNchy7rEqT1Sbl9zPjJAuhgMQ1_pwoHs_LngchT0vFlOWUJ9R4m3BH80Q67xOfMmpkRVNvMTn56FgcnvDFaX76SxZ_iHYfryT7nAas0lR3B6vK9ywuxUGL121pAvomCSXLE3WdbMtcCXC_tmezxefFKI1zBhw9Jsv8ceZEIYW6_Vel89WIyd-uTYM2mt8iNwczMp71dL9Nrrn6Dtk5Gi7K75Lzd0s8NG6wGWf7Mg7pvfCiGMy9GBTX0sbYROXCrM_buPGxRdqvYzzFb-OuiTHC0n13Ab4CUjStQ1iISsfXlBjK3g3T7pGT-dsvrw-Toa9CYkUmuqRKHS9SowStbMWYYTw1oMkyC8ahB4fGM2xHUzBqXZWJQlTCp9Jy4WwO3lrh2H2yVTe1e0DijHtfohHmDOXSCqMsy0qWlzYXXmZpRLJxcbUdio5j74tvOjgfUuieIBoIogNBtIrI882cVV9y45_oV0izDRLLZYcHzfpMD9ynSxDpUpYZbMMSXDymwPCyzHpuFDPc5xHZR4rrPvd0w_R6VoB3xxhIkog8Cwhke_gBa4bsBVgGLKA1Qe5NkMCudjo87io9iItWg9tacDAMZRGRJ5thnIkhcLVrLhEjFKVpWFQ52Y2Tf5-O1MuvoWQ4WNEZWqYReTFu3J9f__viPvw_-D7Z-fRmrj--P_6wS27QwGQqofke2erWl-4RmG9d-Xjg0B9myjw-
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ginsenosides%3A+changing+the+basic+hallmarks+of+cancer+cells+to+achieve+the+purpose+of+treating+breast+cancer&rft.jtitle=Chinese+medicine&rft.au=Jiang%2C+Rui-yuan&rft.au=Fang%2C+Zi-ru&rft.au=Zhang%2C+Huan-ping&rft.au=Xu%2C+Jun-yao&rft.date=2023-09-25&rft.pub=BioMed+Central+Ltd&rft.issn=1749-8546&rft.eissn=1749-8546&rft.volume=18&rft.issue=1&rft_id=info:doi/10.1186%2Fs13020-023-00822-9&rft.externalDocID=A766633200
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1749-8546&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1749-8546&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1749-8546&client=summon